Studying zonulin levels in patients with inflammatory bowel disease and peripheral arthritis

Abstract

BACKGROUND: Currently, disruption of the barrier function of the intestinal mucosa is considered one of the key mechanisms in the pathogenesis of extraintestinal manifestations of inflammatory bowel diseases, especially damage to the musculoskeletal system.

AIM: To study the relationship between the level of zonulin in blood serum and the parameters of the immune status in patients with inflammatory bowel diseases in combination with peripheral arthritis.

MATERIALS AND METHODS: 97 patients with ulcerative colitis and Crohn’s disease have been examined, with peripheral arthritis verified in 47 patients; the control group included 50 patients without peripheral arthritis. Zonulin, tumor necrosis factor α, interleukin-1β, -10, -17A, -23 were determined in blood serum using standard kits for direct enzyme immunoassay.

RESULTS: Patients with peripheral arthritis were younger with an earlier onset of inflammatory bowel diseases (p < 0.001). When assessing the concentration of serum zonulin in the patients with and without arthritis, no significant differences have been found. In the patients with peripheral arthritis, zonulin concentration directly correlated with the level of interleukin-17A (r = 0.323; p = 0.039), interleukin-23 (r = 0.321; p = 0.041).

CONCLUSIONS: According to the data obtained, the use of zonulin as a marker of peripheral arthritis in inflammatory bowel diseases is not recommended. Nevertheless, the correlation of zonulin and the concentrations of interleukin-17А and -23 demonstrates its role in the regulation of mucosal immunity in the development of extraintestinal manifestations of inflammatory bowel diseases.

Keywords

inflammatory bowel disease / ulcerative colitis / Crohn’s disease / extraintestinal manifestations / peripheral arthritis / zonulin / interleukin-17A / interleukin-23

References

[1] Ivashkin VT, Shelygin YuA, Khalif IL, et al. Clinical guide of Russian association of gastroenterology and Russian association of coloproctology on diagnostics and treatment of ulcerative colitis. Koloproktologiya. 2017;(1(59)):6–30. (In Russ.)

[2] Ивашкин В.Т., Шелыгин Ю.А., Халиф И.Л. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации и Ассоциации колопроктологов России по диагностике и лечению язвенного колита // Колопроктология. 2017. № 1(59). С. 6–30.

[3] Ivashkin VT, Shelygin YuA, Khalif IL, et al. Clinical guide of Russian association of gastroenterology and Russian association of coloproctology on diagnostics and treatment of Crohn’s disease. Koloproktologiya. 2017;(2(60)):7–29. (In Russ.)

[4] Ивашкин В.Т., Шелыгин Ю.А., Халиф И.Л. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации и Ассоциации колопроктологов России по диагностике и лечению болезни Крона // Колопроктология. 2017. № 2(60). С. 7–29.

[5] Parfenov AI, Knyazev OV, Kagramanova AV. Systemic manifestations of inflammatory bowel diseases. Therapeutic Archive. 2020;92(2):4–11. (In Russ.) DOI: 10.26442/00403660.2020.02.000535

[6] Парфенов А.И., Каграманова А.В., Князев О.В. Системные проявления воспалительных заболеваний кишечника // Терапевтический архив. 2020. Т. 92, № 2. С. 4–11. DOI: 10.26442/00403660.2020.02.000535

[7] Hedin CRH, Vavricka SR, Stagg AJ, et al. The pathogenesis of extraintestinal manifestations: Implications for IBD research, diagnosis, and therapy. J Crohns Colitis. 2019;13(5):541–554. DOI: 10.1093/ecco-jcc/jjy191

[8] Hedin C.R.H., Vavricka S.R., Stagg A.J. et al. The pathogenesis of extraintestinal manifestations: Implications for IBD research, diagnosis, and therapy // J. Crohns Colitis. 2019. Vol. 13, No. 5. P. 541–554. DOI: 10.1093/ecco-jcc/jjy191

[9] Wang CR, Tsai HW. Seronegative spondyloarthropathy-associated inflammatory bowel disease. World J Gastroenterol. 2023;29(3):450–468. DOI: 10.3748/wjg.v29.i3.450

[10] Wang C.R., Tsai H.W. Seronegative spondyloarthropathy-associated inflammatory bowel disease // World J. Gastroenterol. 2023. Vol. 29, No. 3. P. 450–468. DOI: 10.3748/wjg.v29.i3.450

[11] Ben Nessib D, Ferjani H, Maatallah K, et al. Update on therapeutic management of spondyloarthritis associated with inflammatory bowel disease. Clin Rheumatol. 2020;39(12):3543–3553. DOI: 10.1007/s10067-020-05136-x

[12] Ben Nessib D., Ferjani H., Maatallah K. et al. Update on therapeutic management of spondyloarthritis associated with inflammatory bowel disease // Clin. Rheumatol. 2020. Vol. 39, No. 12. P. 3543–3553. DOI: 10.1007/s10067-020-05136-x

[13] Rumyantseva DG, Erdes ShF. Axial spondyloarthritis: a current look at the concept and evolution of the disease. Modern Rheumatology Journal. 2019;13(4):4–10. (In Russ.) DOI: 10/14412/1996-7012-2019-4-4-10

[14] Румянцева Д.Г., Эрдес Ш.Ф. Аксиальный спондилоартрит: современный взгляд на концепцию и эволюцию болезни // Современная ревматология. 2019. Т. 13, № 4. С. 4–10. DOI: 10/14412/1996-7012-2019-4-4-10

[15] Khusainova GM, Dolgushina AI, Kuznetcova AS. Characteristics of the articular syndrome in patients with inflammatory bowel disease. Experimental and Clinical Gastroenterology. 2020;178(6):95–100. (In Russ.) DOI: 10.31146/1682-8658-ecg-178-6-95-100

[16] Хусаинова Г.М., Долгушина А.И., Кузнецова А.С. Характеристика суставного синдрома у пациентов с воспалительными заболеваниями кишечника // Экспериментальная и клиническая гастроэнтерология. 2020. № 6(178). С. 95–100. DOI: 10.31146/1682-8658-ecg-178-6-95-100

[17] Di Jiang C, Raine T. IBD considerations in spondyloarthritis. Ther Adv Musculoskelet Dis. 2020;12:1759720X20939410. DOI: 10.1177/1759720X20939410

[18] Di Jiang C., Raine T. IBD considerations in spondyloarthritis // Ther. Adv. Musculoskelet. Dis. 2020. Vol. 12. P. 1759720X20939410. DOI: 10.1177/1759720X20939410

[19] Pedersen SJ, Maksymowych WP. The Pathogenesis of ankylosing spondylitis: an update. Curr Rheumatol Rep. 2019;21(10):58. DOI: 10.1007/s11926-019-0856-3

[20] Pedersen S.J., Maksymowych W.P. The pathogenesis of ankylosing spondylitis: an update // Curr. Rheumatol. Rep. 2019. Vol. 21. No. 10. P. 58. DOI: 10.1007/s11926-019-0856-3

[21] Galushko EA, Gordeev AV. Gut microbiome and spondyloarthritis. Experimental and Clinical Gastroenterology. 2019;162(2):120–124. (In Russ.) DOI: 10.31146/1682-8658-ecg-162-2-120-124

[22] Галушко Е.А., Гордеев А.В. Микробиом кишечника и спондилоартриты // Экспериментальная и клиническая гастроэнтерология. 2019. Т. 162, № 2. С. 120–124. DOI: 10.31146/1682-8658-ecg-162-2-120-124

[23] Qaiyum Z, Lim M, Inman RD. The gut-joint axis in spondyloarthritis: immunological, microbial, and clinical insights. Semin Immunopathol. 2021;43(2):173–192. DOI: 10.1007/s00281-021-00845-0

[24] Qaiyum Z., Lim M., Inman R.D. The gut-joint axis in spondyloarthritis: immunological, microbial, and clinical insights // Semin. Immunopathol. 2021. Vol. 43, No. 2. P. 173–192. DOI: 10.1007/s00281-021-00845-0

[25] Osikov MV, Grechishkin MV, Shishkova YuS. State of the microbiota and local immune factors in inflammatory bowel diseases and selection of the experimental model. Yuzhno-Ural’skij medicinskij zhurnal. 2023;1:50–59. (In Russ.)

[26] Осиков М.В., Гречишкин М.В., Шишкова Ю.С. Состояние микробиоты и локальных факторов иммунитета при воспалительных заболеваниях кишечника и выбор экспериментальной модели // Южно-Уральский медицинский журнал. 2023. № 1. С. 50–59.

[27] Fasano A. Zonulin and its regulation of intestinal barrier function: the biological door to inflammation, autoimmunity, and cancer. Physiol Rev. 2011;91(1):151–175. DOI: 10.1152/physrev.00003.2008

[28] Fasano A. Zonulin and its regulation of intestinal barrier function: the biological door to inflammation, autoimmunity, and cancer // Physiol. Rev. 2011. Vol. 91, No. 1. P. 151–175. DOI: 10.1152/physrev.00003.2008

[29] Fasano A. All disease begins in the (leaky) gut: role of zonulin-mediated gut permeability in the pathogenesis of some chronic inflammatory diseases. F1000Res. 2020;31(9):F1000 Faculty Rev-69. DOI: 10.12688/f1000research.20510.1

[30] Fasano A. All disease begins in the (leaky) gut: role of zonulin-mediated gut permeability in the pathogenesis of some chronic inflammatory diseases // F1000Res. 2020. Vol. 31, No. 9. P. F1000 Faculty Rev-69. DOI: 10.12688/f1000research.20510.1

[31] Russian clinical guidelines. Rheumatology. Ed. by E.L. Nasonov. Moscow: GEOTAR-Media; 2017. (In Russ.)

[32] Российские клинические рекомендации. Ревматология / под ред. Е.Л. Насонова. Москва: ГЭОТАР-Медиа, 2017. 464 с.

[33] Ciccia F, Guggino G, Rizzo A, et al. Dysbiosis and zonulin upregulation alter gut epithelial and vascular barriers in patients with ankylosing spondylitis. Ann Rheum Dis. 2017;76(6):1123–1132. DOI: 10.1136/annrheumdis-2016-210000

[34] Ciccia F., Guggino G., Rizzo A. et al. Dysbiosis and zonulin upregulation alter gut epithelial and vascular barriers in patients with ankylosing spondylitis // Ann. Rheum. Dis. 2017. Vol. 76, No. 6. P. 1123–1132. DOI: 10.1136/annrheumdis-2016-210000

[35] Nasonov EL, Korotaeva TV, Rodolfi S, Selmi CF. Prospects for the use of monoclonal antibodies to interleukin 23 Gusеlkumab in psoriatic arthritis: New data. Rheumatology Science and Practice. 2022;60(1):80–90. (In Russ.) DOI: 10.47360/1995-4484-2022-80-90

[36] Насонов Е.Л., Коротаева Т.В., Родолфи С., Селми К.Ф. Перспективы применения моноклональных антител к интерлейкину 23 гуселькумаба при псориатическом артрите: новые данные // Научно-практическая ревматология. 2022. Т. 60, № 1. С. 80–90. DOI: 10.47360/1995-4484-2022-80-90

[37] Chmielińska M, Olesińska M, Romanowska-Próchnicka K, Szukiewicz D. Haptoglobin and its related protein, zonulin – what is their role in spondyloarthropathy? J Clin Med. 2021;10(5):1131. DOI: 10.3390/jcm10051131

[38] Chmielińska M., Olesińska M., Romanowska-Próchnicka K., Szukiewicz D. Haptoglobin and its related protein, zonulin – what is their role in spondyloarthropathy? // J. Clin. Med. 2021. Vol. 10, No. 5. P. 1131. DOI: 10.3390/jcm10051131

[39] Zybina NN, Nikonov EL, Gershtein ES, et al. Zonulin is a marker of epithelial and endothelial barrier functions in non-communicable diseases (narrative review). Russian Journal of Evidence-based Gastroenterology. 2022;11(1):28–44. (In Russ.) DOI: 10.17116/dokgastro20221101128

[40] Зыбина Н.Н., Никонов Е.Л., Герштейн Е.С. и др. Зонулин как маркер проницаемости клеточных контактов при соматических и онкологических заболеваниях (обзор литературы) // Доказательная гастроэнтерология. 2022. Т. 11, № 1. С. 28–44. DOI: 10.17116/dokgastro20221101128

[41] Wang X, Memon AA, Palmér K, et al. The association of zonulin-related proteins with prevalent and incident inflammatory bowel disease. BMC Gastroenterol. 2022;22(1):3. DOI: 10.1186/s12876-021-02075-y

[42] Wang X., Memon A.A., Palmér K. et al. The association of zonulin-related proteins with prevalent and incident inflammatory bowel disease // BMC Gastroenterol. 2022. Vol. 22, No. 1. P. 3. DOI: 10.1186/s12876-021-02075-y

RIGHTS & PERMISSIONS

Eco-Vector